| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30003686 | HIV | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
| TVIS30088900 | HIV | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
| TVIS30076730 | HIV | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
| TVIS30060933 | HIV | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
| TVIS30060934 | HIV | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
| TVIS20011880 | HPV | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
| TVIS20058749 | HPV | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
| TVIS44036219 | HTLV-1 | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | PDE5A |
|---|---|
| DrugBank ID | DB00203 |
| Drug Name | Sildenafil |
| Target ID | BE0000182 |
| UniProt ID | O76074 |
| Regulation Type | inhibitor |
| PubMed IDs | 12614192; 11752352; 12414329; 12477710; 12554648; 16735511; 17959709; 12567500; 17979301 |
| Citations | Carson CC: Long-term use of sildenafil. Expert Opin Pharmacother. 2003 Mar;4(3):397-405.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Corbin JD, Francis SH, Webb DJ: Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology. 2002 Sep;60(2 Suppl 2):4-11.@@Kruuse C, Thomsen LL, Birk S, Olesen J: Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain. 2003 Jan;126(Pt 1):241-7.@@Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, Beavo JA: PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J. 2003 Feb 3;22(3):469-78.@@Wang H, Liu Y, Huai Q, Cai J, Zoraghi R, Francis SH, Corbin JD, Robinson H, Xin Z, Lin G, Ke H: Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. J Biol Chem. 2006 Jul 28;281(30):21469-79. Epub 2006 May 30.@@Wang H, Ye M, Robinson H, Francis SH, Ke H: Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Mol Pharmacol. 2008 Jan;73(1):104-10. Epub 2007 Oct 24.@@Wang J, Re J, Wang Z: [Mode of action of sildenafil]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1999 Dec;21(6):493-6.@@Zoraghi R, Francis SH, Corbin JD: Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors. Biochemistry. 2007 Nov 27;46(47):13554-63. Epub 2007 Nov 3. |
| Groups | Approved; Investigational |
| Direct Classification | Benzenesulfonamides |
| SMILES | CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1 |
| Pathways | |
| PharmGKB | PA451346 |
| ChEMBL | CHEMBL192 |
